Circulating microRNAs in Alzheimer’s disease: the search for novel biomarkers

• Main Authors: Veronique eDorval, Peter T Nelson, Sébastien S Hébert
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2013-08-01
• Series: Frontiers in Molecular Neuroscience
• Subjects: Mild Cognitive Impairment; Alzheimer's disease; microRNA; biomarker; diagnosis
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fnmol.2013.00024/full

Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly. While advancements have been made in understanding the genetic and molecular basis of AD, the clinical diagnosis of AD remains difficult and post-mortem confirmation is often required. Furthermore, the onset of neurodegeneration precedes clinical symptoms by approximately a decade. Consequently, there is a crucial need for an early and accurate diagnosis of AD, which can potentially lead to strategies that can slow down or stop the progression of neurodegeneration and dementia. Recent advances in the noncoding RNA field have shown that microRNAs (miRNAs) can function as powerful biomarkers in human diseases. Studies are emerging suggesting that circulating miRNAs in the cerebrospinal fluid (CSF) and blood serum have characteristic changes in AD patients. Whether miRNAs can be used in AD diagnosis, alone or in combination with other AD biomarkers (e.g., amyloid and tau), warrants further investigation.